DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA581823
Title:
Preclinical Evaluation to Specifically Target Ovarian Cancer with Folic Acid-Conjugated Nanoceria
Descriptive Note:
Annual rept. 20 May 2011 - 19 May 2012
Corporate Author:
HENRY FORD HEALTH SYSTEM DETROIT MI
Report Date:
2012-06-01
Pagination or Media Count:
15.0
Abstract:
Despite the fact that there have been significant developments in anti-cancer technology, ovarian cancer still remains one of the leading causes of gynecological cancer deaths in the United States. To contribute towards novel approaches with minimal toxicity in treatment of ovarian cancer we proposed the present work, where we are integrating the field of nanotechnology with ovarian cancer cell s unique property of overexpressing folic acid receptor alpha FR-alpha to specifically target ovarian cancer. A cerium oxide nanoparticle, called Nanoceria NCe, that has the ability to act as an anti-oxidant in similar capacity as biological anti-oxidants was selected. NCe in our hands exhibited efficacy in inhibiting ovarian tumor growth in vivo. Taking advantage of the nanotechnology, NCe was conjugated with molecules of folic acid to specifically target ovarian tumors as they are known to over-express folate receptor. This would result in specific killing of ovarian cells by NCe while minimizing toxicity to normal tissue. Dr Seal s laboratory UCF was able to successfully conjugate NCe to folic acid to prepare folic acid tagged Nanoceria called FA-NCe. FA-NCe was tested in vitro and was observed to have higher anti-growth activity against ovarian cancer cells. This indicates that when given in animals, it maybe more potent in inhibiting ovarian tumor growth.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
